

## PRESS RELEASE - TRANSLATION

AUGUSTI 10, 2022

---

### Nanologica Expands Management Team for Increased Focus on Chromatography

**Nanologica AB (publ) has expanded its management team with Katarina Alenäs, SVP Chromatography, as part of intensifying the company's efforts within preparative chromatography.**

Katarina Alenäs took up her position as SVP Chromatography at Nanologica in the beginning of March, and most recently came from a role as Business Team Manager Sweden and Finland, Country General Manager Sweden and chairman of the board of Agilent Technologies Sweden AB. Katarina has a solid background and a strong network in the field of chromatography, an area she has worked in most of her career.

*"Katarina is a strong addition to the management team and further strengthens our focus on preparative chromatography. Katarina leads the work with launching our preparative silica and with securing orders and signing supply agreements. We are currently in an exciting time and look forward to what we believe will be an eventful autumn",* Andreas Bhagwani, CEO of Nanologica comments.

Katarina joins the management team with immediate effect.

**For further information, please contact:**

Johanna Johansson, Director IR, Communications and Marketing  
Ph: +46 72 211 21 90 or e-mail: [ir@nanologica.com](mailto:ir@nanologica.com)

**About Nanologica AB (publ)**

Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung, to provide new treatment options for patients with lung diseases. Nanologica is headquartered in Södertälje, and the company's share (NICA) is listed for trade on Nasdaq Stockholm Main Market since 29 mars, 2022. For further information, please visit [www.nanologica.com](http://www.nanologica.com).